Alexion's long-acting C5 inhibitor meets in Phase III

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said that ALXN1210, its long-acting formulation of Soliris eculizumab, met the co-primary and four key secondary endpoints in the Phase III ALXN1210-PNH-301 trial to treat paroxysmal nocturnal hemoglobinuria (PNH). The company reiterated its plans to submit regulatory applications for ALXN1210 next half in the U.S., EU and Japan to treat PNH.

Buysiders have been on the lookout for the ALXN1210 data. International Biotechnology Trust plc's Ailsa Craig previously told BioCentury that ALXN1210 “is a product that they hope will replace Soliris so that they can maintain their monopoly on the space" (see BioCentury, Jan. 5)...